Skip to main content
. 2021 Apr 28;12:671859. doi: 10.3389/fphar.2021.671859

FIGURE 2.

FIGURE 2

Changes in systolic (A) and diastolic (B) blood pressure 2 and 24 h after REL-1017 administration. The data represent differences from baseline in BP measurements taken during treatment. ***p < 0.001 and ****p < 0.0001 vs. placebo.